Der HER-2-Status im lokal fortgeschrittenen Rektumkarzinom: Positivitätsrate, mögliche prädiktive und prognostische Bedeutung

Frequency of HER-2 positivity in rectal cancer and prognosis

by Hanna Styczen
Doctoral thesis
Date of Examination:2013-11-12
Date of issue:2013-08-26
Advisor:PD Dr. Torsten Liersch
Referee:PD Dr. Torsten Liersch
Referee:Prof. Dr. Philipp Ströbel
Persistent Address: http://dx.doi.org/10.53846/goediss-4006

 

 

Files in this item

Name:Promotion_HS_FINAL_ohne_Lebenslauf.pdf
Size:2.71Mb
Format:PDF

The following license files are associated with this item:

Abstract

English

In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3 or silver in situ hybridization ratios of ≥2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P=0.1) and a benefit in CSS (P=0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P<0.00001) and R status (P=0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials.
Keywords: HER-2; rectal cancer
Schlagwörter: HER-2-Status; Rektumkarzinom
 
Statistik